Open access · US-GOV via ClinicalTrials.gov Clinical trial

Third-Party COVID-19-Specific Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients With COVID-19 Infection

Authors not listed

Thomas Jefferson University · 2021

Dysbiosis Human Randomized controlled trial

Abstract

This clinical trial will study the safety and efficacy of COVID-19-specific T cells when given as treatment to adult patients (age ≥ 18 years) with a COVID-19 infection. This immunologic treatment is aimed at patients, who are at high risk of progression due to their advanced age, or other underlying health conditions. The outcomes of patients receiving the T cells (Arm A) will be compared to patients treated with standard of care (Arm B).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-19 MST

Cite this

APA

Anonymous. (2021). Third-Party COVID-19-Specific Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients With COVID-19 Infection. <em>Thomas Jefferson University</em>. https://clinicaltrials.gov/study/NCT04765449

Vancouver

Anonymous. Third-Party COVID-19-Specific Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients With COVID-19 Infection. Thomas Jefferson University. 2021.

BibTeX

@misc{anon2021ThirdP, title = {Third-Party COVID-19-Specific Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients With COVID-19 Infection}, author = {Anonymous}, journal = {Thomas Jefferson University}, year = {2021}, }